As a company listed on the Euronext Growth market in Paris, Europlasma undertakes to providing the financial community with regular, transparent and accessible information and in compliance with stock market regulations
After closing of the trading day on October 31, 2017, Europlasma granted 152,405,521 warrants (BSAR C) for the benefit of the company’s shareholders on the basis of one BSAR C for one Europlasma ordinary share registered, giving the right to subscribe for a total of 38,101,380 new shares.
